Monthly injections of the tetrapeptide Epitalon increased both mean and maximum lifespan by 12.3% in female mice while reducing malignant lymphoma incidence and slowing age-related decline.
12.3% lifespan extensionBoth mean and maximum lifespan increased by 12.3% in female mice receiving monthly Epitalon courses from age 3 months
What the researchers found
Subcutaneous Epitalon injections (0.1 µg per mouse, 5 consecutive days per month starting at 3 months of age) in female SHR mice increased both mean and maximum lifespan by 12.3% compared to untreated controls.
The peptide did not increase total spontaneous tumor incidence but significantly decreased the incidence of malignant lymphomas. Additionally, Epitalon preserved estrous cycle function longer, slowed age-related deterioration of immune parameters, and reduced the frequency of chromosome aberrations in bone marrow cells of old mice.
Why it matters
Epitalon is one of the Khavinson peptide bioregulators — short synthetic peptides developed in Russia as potential anti-aging interventions. This study is frequently cited in longevity research because it shows a single, very small peptide simultaneously affecting multiple aging biomarkers: lifespan, cancer incidence, reproductive aging, immune function, and chromosomal stability. If these results translate beyond mice, the implications for aging biology would be significant.
How the study worked
Female Swiss-derived SHR mice received subcutaneous injections of Epitalon (Ala-Glu-Asp-Gly) at 0.1 µg per mouse for 5 consecutive days each month, beginning at age 3 months and continuing through life. Controls received no treatment. Outcomes measured included lifespan, spontaneous tumor incidence, estrous cycle function, immune parameters, and chromosome aberration frequency in bone marrow cells.
What this study cannot tell us
This is a single-lab study from the Khavinson/Anisimov research group, which has not been independently replicated by other laboratories. The SHR mouse strain is specific and may not represent general aging biology. The abstract does not report group sizes, making it difficult to assess statistical power. The extremely low dose (0.1 µg) raises questions about mechanism and bioavailability. No human studies of Epitalon for lifespan extension exist.
How to read the evidence
This is a preclinical animal study from a single research group (Anisimov/Khavinson) that has not been independently replicated. While the study design is reasonable, the lack of independent confirmation and the absence of human data place the evidence at a low level for clinical applicability.
When this study was published
Published in 2003, this study is over two decades old. It remains one of the most-cited Epitalon studies, but the lack of subsequent independent replication or human trials limits how much weight should be placed on it.
The bigger picture
Epitalon belongs to a class of short peptide bioregulators championed by Russian gerontologist Vladimir Khavinson. This study is one of several from Anisimov and Khavinson's group showing lifespan extension in rodents with these tetrapeptides. While the results are intriguing, this line of research has remained largely within the Russian scientific community, with limited independent replication by Western labs — a gap that leaves the findings promising but incompletely validated.
Questions still open
- Has any independent laboratory replicated Epitalon's lifespan extension effects in mice or other organisms?
- What is Epitalon's proposed mechanism of action — does it work through telomerase activation, pineal gland function, or another pathway?
- Would these effects be seen in male mice or in other mouse strains with different aging and cancer profiles?
Common questions
What is Epitalon and how is it supposed to work?
Can people take Epitalon to live longer?
Read the original research
Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice.
Biogerontology, 4(4), 193-202
Citation
Anisimov, V N; Khavinson, V Kh; Popovich, I G; Zabezhinski, M A; Alimova, I N; Rosenfeld, S V; Zavarzina, N Yu; Semenchenko, A V; Yashin, A I. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice.. Biogerontology, 4(4), 193-202. https://doi.org/10.1023/A:1025114230714